112 related articles for article (PubMed ID: 22880290)
1. [Basal insulin has a "neutral effect" on cardiovascular events].
Overbeck P
MMW Fortschr Med; 2012 Jun; 154(12):24. PubMed ID: 22880290
[No Abstract] [Full Text] [Related]
2. Learning from ORIGIN.
Bloomgarden ZT
J Diabetes; 2012 Sep; 4(3):191-2. PubMed ID: 22716648
[No Abstract] [Full Text] [Related]
3. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
Lombard L; Distiller L; Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
[No Abstract] [Full Text] [Related]
4. Treatment persistence in the use of basal insulins in Poland and Germany
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
[TBL] [Abstract][Full Text] [Related]
5. Lessons from glargine trials: what is the goal fasting glucose with basal insulin?
Bloomgarden Z; Handelsman Y
J Diabetes; 2014 Jul; 6(4):271-3. PubMed ID: 24656089
[No Abstract] [Full Text] [Related]
6. Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
Chang CH; Chuang LM
J Diabetes Investig; 2018 Jul; 9(4):728-730. PubMed ID: 29140602
[No Abstract] [Full Text] [Related]
7. Comparative efficacy and safety of basal insulins: A review.
Vargas-Uricoechea H; Aschner P
Diabetes Metab Syndr; 2021; 15(6):102318. PubMed ID: 34695771
[TBL] [Abstract][Full Text] [Related]
8. [Improving insulin therapy in type 2 diabetes. Conquering barriers and assuring quality of life].
MMW Fortschr Med; 2014 Dec; 156(21-22):99. PubMed ID: 25608421
[No Abstract] [Full Text] [Related]
9. [Early insulin therapy in type 2 diabetes?].
Birkeland KI
Tidsskr Nor Laegeforen; 2012 Oct; 132(19):2151-2. PubMed ID: 23076480
[No Abstract] [Full Text] [Related]
10. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
[TBL] [Abstract][Full Text] [Related]
11. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
[TBL] [Abstract][Full Text] [Related]
12. ["Very good metabolic control by early insulin administration"].
Schumm-Draeger PM
MMW Fortschr Med; 2012 Jun; 154(12):25. PubMed ID: 22880291
[No Abstract] [Full Text] [Related]
13. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.
Dungan KM; Buse JB; Herman WH; Arakaki RF; Jiang HH; Jacobson JG; Fahrbach JL
Diabetes Res Clin Pract; 2012 Jun; 96(3):e66-9. PubMed ID: 22421598
[TBL] [Abstract][Full Text] [Related]
14. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
15. Basal insulin and cardiovascular and other outcomes.
Leow MK
N Engl J Med; 2012 Nov; 367(18):1763; author reply 1763-4. PubMed ID: 23113497
[No Abstract] [Full Text] [Related]
16. Basal insulin and cardiovascular and other outcomes.
Ceriello A
N Engl J Med; 2012 Nov; 367(18):1762-3; author reply 1763-4. PubMed ID: 23113496
[No Abstract] [Full Text] [Related]
17. Basal insulin and cardiovascular and other outcomes.
Schernthaner G; Currie CJ
N Engl J Med; 2012 Nov; 367(18):1762; author reply 1763-4. PubMed ID: 23113495
[No Abstract] [Full Text] [Related]
18. Basal insulin and cardiovascular and other outcomes.
Vigneri R; Vigneri P; Frittitta L
N Engl J Med; 2012 Nov; 367(18):1761-2; author reply 1763-4. PubMed ID: 23113494
[No Abstract] [Full Text] [Related]
19. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
Bloomgarden ZT
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
[No Abstract] [Full Text] [Related]
20. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
